Home › Companies › Lyell Immunopharma, Inc. › 2025-2026
At Lyell Immunopharma, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 64 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 283 separate fund positions. On the most widely held item on that ballot — Approval, on a non-binding advisory basis, of the compensation of the Company's named executive… — FOR was 99.9% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Lyell Immunopharma, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 15, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Lyell Immunopharma, Inc.’s Form 8-K, filed June 15, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 10, 2026: 5 items on Lyell Immunopharma, Inc.’s Form 8-K, filed June 15, 2026: 5 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Lyell Immunopharma, Inc. in the interactive database Compare manager voting policies
These tallies are Lyell Immunopharma, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 15, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Richard Klausner, M.D. | 12,177,913 | -- | -- | 99,627 | 3,429,286 | 99.1% | Not verified | — |
| Elect Director: Otis Brawley, M.D. | 11,866,210 | -- | -- | 411,330 | 3,429,286 | 97% | Not verified | — |
| Elect Director: William Rieflin | 12,192,547 | -- | -- | 84,993 | 3,429,286 | 99.3% | Not verified | — |
| 2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. | 15,674,347 | 30,758 | 1,721 | -- | -- | 99.8% | Not verified | — |
| 3. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. | 11,860,218 | 6,613 | 410,709 | -- | 3,429,286 | 99.9% | Not verified | — |
Source: Lyell Immunopharma, Inc., Form 8-K, filed with the SEC on June 15, 2026 — read the filing on EDGAR.
Each item below shows how the 64 asset managers that disclosed a Lyell Immunopharma, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Otis Brawley, M.D.
Lyell Immunopharma, Inc.’s own tally for this item (“Elect Director: Otis Brawley, M.D.”): 11,866,210 for, 411,330 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 907,334 for, 81,750 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 673,658 | 0 | 1 | 1,249 | For |
| Fidelity | 99,739 | 0 | 0 | 0 | For |
| Charles Schwab | 86,117 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 28,350 | Withhold |
| SEI | 21,220 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 18,000 | Withhold |
| American Century | 0 | 0 | 0 | 16,142 | Withhold |
| Dimensional | 0 | 0 | 0 | 13,451 | Withhold |
| BlackRock | 10,061 | 0 | 0 | 0 | For |
| Invesco | 7,496 | 0 | 0 | 0 | For |
| T. Rowe Price | 6,557 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 2,211 | Withhold |
| Goldman Sachs | 1,969 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 923 | Withhold |
| Victory Capital | 0 | 0 | 0 | 827 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 517 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 359 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 145 | Withhold |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 93 | Withhold |
Combines 3 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: Richard Klausner, M.D.
Lyell Immunopharma, Inc.’s own tally for this item (“Elect Director: Richard Klausner, M.D.”): 12,177,913 for, 99,627 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 972,081 for, 17,004 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 673,659 | 0 | 0 | 1,249 | For |
| Fidelity | 99,739 | 0 | 0 | 0 | For |
| Charles Schwab | 86,117 | 0 | 0 | 0 | For |
| Northern Trust | 28,350 | 0 | 0 | 0 | For |
| SEI | 21,220 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 18,000 | 0 | 0 | 0 | For |
| American Century | 16,142 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 13,451 | Withhold |
| BlackRock | 10,061 | 0 | 0 | 0 | For |
| Invesco | 7,496 | 0 | 0 | 0 | For |
| T. Rowe Price | 6,557 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 2,211 | Withhold |
| Goldman Sachs | 1,969 | 0 | 0 | 0 | For |
| ProShares | 923 | 0 | 0 | 0 | For |
| Victory Capital | 827 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 517 | 0 | 0 | 0 | For |
| John Hancock | 359 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 145 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 93 | Withhold |
Combines 3 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
Description as filed by funds: Election of Class II Directors: William Rieflin
Lyell Immunopharma, Inc.’s own tally for this item (“Elect Director: William Rieflin”): 12,192,547 for, 84,993 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.3% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 972,081 for, 17,004 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 673,659 | 0 | 0 | 1,249 | For |
| Fidelity | 99,739 | 0 | 0 | 0 | For |
| Charles Schwab | 86,117 | 0 | 0 | 0 | For |
| Northern Trust | 28,350 | 0 | 0 | 0 | For |
| SEI | 21,220 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 18,000 | 0 | 0 | 0 | For |
| American Century | 16,142 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 13,451 | Withhold |
| BlackRock | 10,061 | 0 | 0 | 0 | For |
| Invesco | 7,496 | 0 | 0 | 0 | For |
| T. Rowe Price | 6,557 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 0 | 2,211 | Withhold |
| Goldman Sachs | 1,969 | 0 | 0 | 0 | For |
| ProShares | 923 | 0 | 0 | 0 | For |
| Victory Capital | 827 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 517 | 0 | 0 | 0 | For |
| John Hancock | 359 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 145 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 93 | Withhold |
Combines 4 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.
Lyell Immunopharma, Inc.’s own tally for this item (“3. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”): 11,860,218 for, 6,613 against, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 674,906 | 0 | 2 | 0 | For |
| Fidelity | 99,739 | 0 | 0 | 0 | For |
| Charles Schwab | 86,117 | 0 | 0 | 0 | For |
| Northern Trust | 28,350 | 0 | 0 | 0 | For |
| SEI | 21,220 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 18,000 | 0 | 0 | 0 | For |
| American Century | 16,142 | 0 | 0 | 0 | For |
| Dimensional | 13,451 | 0 | 0 | 0 | For |
| BlackRock | 10,061 | 0 | 0 | 0 | For |
| Invesco | 7,496 | 0 | 0 | 0 | For |
| T. Rowe Price | 6,557 | 0 | 0 | 0 | For |
| Jackson National | 2,211 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,969 | 0 | 0 | 0 | For |
| ProShares | 923 | 0 | 0 | 0 | For |
| Victory Capital | 827 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 517 | 0 | 0 | 0 | For |
| John Hancock | 359 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 145 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 93 | 0 | 0 | 0 | For |
Fund voting reports, all 19 managers: 989,083 for, 2 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 3,247,162 | 0 | 0 | 0 | For |
| Foresite Capital Management IV, LLC | 800,399 | 0 | 0 | 0 | For |
| Decheng Capital LLC | 692,050 | 0 | 0 | 0 | For |
| Foresite Capital Management V, LLC | 477,078 | 0 | 0 | 0 | For |
| Donor Advised Charitable Giving, Inc. | 0 | 0 | 0 | 0 | Not Voted |
| Citadel | 339,612 | 0 | 0 | 0 | For |
| BROWN ADVISORY INC | 170,294 | 0 | 0 | 0 | For |
| BlackRock | 119,689 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 116,837 | 0 | 0 | 0 | For |
| Vanguard | 94,634 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 94,460 | 0 | 0 | 0 | For |
| Charles Schwab | 86,131 | 0 | 0 | 0 | For |
| T. Rowe Price | 32,827 | 0 | 0 | 0 | For |
| CANADA PENSION PLAN INVESTMENT BOARD | 29,411 | 0 | 0 | 0 | For |
| SEI | 21,220 | 0 | 0 | 0 | For |
| Renaissance | 20,369 | 0 | 0 | 0 | For |
| Clearstead Advisors, LLC | 19,138 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 18,000 | 0 | 0 | 0 | For |
| Northern Trust | 17,127 | 0 | 0 | 0 | For |
| American Century | 16,142 | 0 | 0 | 0 | For |
| Dimensional | 13,650 | 0 | 0 | 0 | For |
| Velan Capital Investment Management LP | 12,000 | 0 | 0 | 0 | For |
| State Street | 11,000 | 0 | 0 | 0 | For |
| Invesco | 7,496 | 0 | 0 | 0 | For |
| Two Sigma | 7,391 | 0 | 0 | 0 | For |
Institutional-manager reports, all 55 managers: 6,488,624 for, 66 against, 382,764 not voted. Showing the 25 largest; every one is in the interactive database (link above).
99.8% Majority: yes · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.
Lyell Immunopharma, Inc.’s own tally for this item (“2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 15,674,347 for, 30,758 against, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 19 asset managers below reported 989,085 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 674,908 | 0 | 0 | 0 | For |
| Fidelity | 99,739 | 0 | 0 | 0 | For |
| Charles Schwab | 86,117 | 0 | 0 | 0 | For |
| Northern Trust | 28,350 | 0 | 0 | 0 | For |
| SEI | 21,220 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 18,000 | 0 | 0 | 0 | For |
| American Century | 16,142 | 0 | 0 | 0 | For |
| Dimensional | 13,451 | 0 | 0 | 0 | For |
| BlackRock | 10,061 | 0 | 0 | 0 | For |
| Invesco | 7,496 | 0 | 0 | 0 | For |
| T. Rowe Price | 6,557 | 0 | 0 | 0 | For |
| Jackson National | 2,211 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,969 | 0 | 0 | 0 | For |
| ProShares | 923 | 0 | 0 | 0 | For |
| Victory Capital | 827 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 517 | 0 | 0 | 0 | For |
| John Hancock | 359 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 145 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 93 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 23,334,087 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.89% |
| 2 | Fidelity | 0.43% |
| 3 | Charles Schwab | 0.37% |
| 4 | Northern Trust | 0.12% |
| 5 | SEI | 0.09% |
| 6 | BRIDGEWAY FUNDS INC | 0.08% |
| 7 | American Century | 0.07% |
| 8 | Dimensional | 0.06% |
| 9 | BlackRock | 0.04% |
| 10 | Invesco | 0.03% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ARCH Venture Management, LLC | 13.92% |
| 2 | Foresite Capital Management IV, LLC | 3.43% |
| 3 | Decheng Capital LLC | 2.97% |
| 4 | Foresite Capital Management V, LLC | 2.04% |
| 5 | Donor Advised Charitable Giving, Inc. | 1.64% |
| 6 | Citadel | 1.46% |
| 7 | BROWN ADVISORY INC | 0.73% |
| 8 | BlackRock | 0.51% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 0.50% |
| 10 | Vanguard | 0.41% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with ARCH Venture Partners | 13.92% | DEF14A |
| ARCH Venture Fund IX, L.P. | 13.92% | 13G |
| Innovative Cellular Therapeutics Holdings Limited | 12.86% | 13G |
| Explore Investments LLC | 6.55% | 13G |
| Gates Frontier, LLC | 6.55% | DEF14A |
| Glaxo Group Limited | 6.48% | DEF14A |
| Entities affiliated with Foresite Capital | 6.23% | DEF14A |
| EULER FUND, L.P. | 6.11% | 13G |
| MWG Caph Ltd | 4.32% | 13G |
| Vanguard Group | 3.54% | 13F |
Percentages above are of 23,334,087 shares outstanding, as reported by Lyell Immunopharma, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Lyell Immunopharma, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Lyell Immunopharma, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
proxyvotesnow.com, “Lyell Immunopharma (LYEL) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/lyell-immunopharma-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.